FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:85-86 July 7, 2005 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Harrison, C. N. PubMed Citation

Essential thrombocythemia is one of the chronic myeloproliferative disorders, a heterogeneous group of diseases involving clonal hematopoietic stem cells that also includes polycythemia vera, idiopathic myelofibrosis, and chronic myelogenous leukemia.¹ Among these disorders, essential thrombocythemia has the most favorable outcome: patients with this disease have a life span that nearly rivals that of a healthy population matched by age and sex.² The principal causes of death in patients with essential thrombocythemia are thrombosis, hemorrhage, and progression to myelofibrosis or acute myelogenous leukemia. The myelosuppressive therapy that prevents vascular events in essential thrombocythemia may itself increase the risk of transformation to . . . [Full Text of this Article]

Source Information

From the Division of Hematology, Ospedali Riuniti, Bergamo, Italy.

This article has been cited by other articles:

• Carobbio, A., Finazzi, G., Antonioli, E., Guglielmelli, P., Vannucchi, A. M., Delaini, F., Guerini, V., Ruggeri, M., Rodeghiero, F., Rambaldi, A., Barbui, T. (2008). Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112: 3135-3137 [Abstract] [Full Text]  
• Patrono, C., Rocca, B. (2008). Aspirin: Promise and Resistance in the New Millennium. Arterioscler. Thromb. Vasc. Bio. 28: s25-s32 [Abstract] [Full Text]  
• Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A., Barbui, T. (2007). Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109: 2310-2313 [Abstract] [Full Text]  
• Vannucchi, A. M., Barbui, T. (2007). Thrombocytosis and Thrombosis. ASH Education Book 2007: 363-370 [Abstract] [Full Text]  
• Barbui, T., Finazzi, G. (2006). Myeloproliferative Disease in Pregnancy and Other Management Issues. ASH Education Book 2006: 246-252 [Abstract] [Full Text]